| Palbociclib | Nilotinib | |
|---|---|---|
| What it is | Kinase Inhibitor | Kinase Inhibitor |
| Used for | is a kinase inhibitor indicated: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial e… | Nilotinib capsules are a kinase inhibitor indicated for the treatment of: Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Adu… |
| Usual adult dose | Not on the label | Adult Dose: Newly diagnosed Ph+ CML-CP: 300 mg orally twice daily. |
| Children | Recommended Pediatric Dose: Newly Diagnosed Ph+ CML-CP or Ph+ CML-CP resistant or intolerant to prior TKI therapy: 230 mg/m 2 orally twice daily, rounded to the nearest 50 mg dose (to a maximum single dose of 400 mg). | |
| Prescription (U.S.) | Yes | Yes |
| Common side effects | The following clinically significant adverse reactions are described elsewhere in the labeling: • Neutropenia [see Warnings and Precautions (5.1) ] • ILD/Pneumonitis [see Warnings and Precautions (5.2) ] Most common adverse reacti… | The following clinically significant adverse reactions can occur with nilotinib and are discussed in greater detail in other sections of labeling: Myelosuppression [ see Warnings and Precautions (5.1) ] QT Prolongation [ see Boxed… |
| Serious warning | Not on the label | and SUDDEN DEATHS Nilotinib prolongs the QT interval. Prior to nilotinib administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies [ see Warnings and Precauti… |
| Pregnancy | 8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action, IBRANCE can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . T… | 8.1 Pregnancy Risk Summary Based on findings from animal studies and the mechanism of action, nilotinib can cause fetal harm when administered to a pregnant woman [ see Clinical Pharmacology (12.1) ]… |
From the official U.S. labels. Brands and strengths differ between countries.
Neither official label mentions the other. That does not prove they are safe together: ask a pharmacist, and use the free interaction checker.
Check them togetherPalbociclib is kinase Inhibitor and Nilotinib is kinase Inhibitor. Palbociclib is used for: is a kinase inhibitor indicated: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial e… Nilotinib is used for: Nilotinib capsules are a kinase inhibitor indicated for the treatment of: Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Adu…
Neither official label mentions the other. That does not prove they are safe together: ask a pharmacist, and use the free interaction checker.
It depends on what you are treating, your health and other medicines. Your doctor or pharmacist can tell you which one suits you; this page shows what each official label says.